Guest Editors:
Ryan C. Fields: Washington University School of Medicine in St. Louis, USA
Anna Golebiewska: Luxembourg Institute of Health, Luxembourg
BMC Cancer has published this Collection on novel in vitro and in vivo cancer models which can help elucidating the mechanisms involved in tumour onset and progression, leading to the development of new therapeutic treatments.
Ryan C. Fields: Washington University School of Medicine in St. Louis, USA
Prof. Fields is the Chief of Surgical Oncology and serves as Director of the Washington University Solid Tumor Tissue Bank and Registry. He is also the Co-Leader of the Solid Tumor Therapeutics Program (STTP) and the Melanoma and Cutaneous Oncology Program at the Alvin J. Siteman NCI-designated Comprehensive Cancer Center at Washington University School of Medicine in St. Louis, Missouri. His research focuses on three main areas: (1) mechanisms of cancer metastases, (2) cancer “-omics”, and (3) novel in vitro and small animal models of cancer. In the area of cancer modelling, he is working to improve the evaluation of diagnostics and therapeutics by developing novel small animal and in vitro models of cancer. He has significant expertise and experience leading large-scale human tumor collection efforts. He has an IRB-approved tumor collection and patient-derived xenografting (PDX), cell line, and organoid creation effort. He works in a multi-disciplinary, collaborative effort to evaluate and translate these model systems into tools that can be used to evaluate novel therapeutics in translational oncology.
Anna Golebiewska: Luxembourg Institute of Health, Luxembourg
Dr. Anna Golebiewska is Group leader of the NORLUX Neuro-Oncology laboratory at the Department of Cancer Research, Luxembourg Institute of Health. She has a background in molecular and cellular biology and obtained her PhD in stem cell research. Her work focuses on understanding brain tumor biology and development of clinically relevant animal models. She is particularly interested in the various aspects of tumor heterogeneity and plasticity. Her lab developed a large collection of glioma patient-derived organoids and orthotopic xenografts for preclinical research and drug testing.
BMC Cancer has published this Collection on pre-clinical cancer models.
Cancer models are indispensable research tools, as they help elucidating the mechanisms involved in tumour onset and progression, leading to the development of new therapeutic treatments. While widely-used conventional two-dimensional cell models have been the gold standard for many decades, some of their main limitations include the lack of representation of the stromal population, the absence of a three-dimensional structure, and a poor representation of inter-tumour and intra-tumour heterogeneity. Therefore, a multitude of novel cancer models are emerging, which can advance the understanding of tumour pathophysiology and behavior. This will ultimately help improving patients’ clinical outcomes, through the introduction of more personalized and targeted treatments in the clinical setting.
In recognition of the growing field of research, BMC Cancer welcomed submissions to this collection ‘Advances in pre-clinical cancer models’. Topics of interest for this special issue included:
Image credit: Hyungkeun/ Getty
Histiocytoses are rare disorders manifested by increased proliferation of pathogenic myeloid cells sharing histological features with macrophages or dendritic cells and accumulating in various organs, i.a., bo...
Preclinical in vivo cancer models are essential tools for investigating tumor progression and response to treatment prior to clinical trials. Although treatment modalities are regularly assessed in mice upon t...
Myxofibrosarcoma is a rare malignant soft tissue sarcoma characterised by multiple local recurrence and can become of higher grade with each recurrence. Consequently, myxofibrosarcoma represents a burden for p...
Hepatocellular carcinoma (HCC), the most common primary liver cancer, prevails mainly in males and has long been attributed to androgens and higher circumstantial levels of interleukin-6 (IL-6) produced by res...
Heterogeneous tumor cells are thought to be a significant factor in the failure of endocrine therapy in estrogen receptor-positive (ER+) cancers. Culturing patient-derived breast cancer cells (PDBCCs) provides...
3D culture is increasingly used in cancer research, as it allows the growth of cells in an environment that mimics in vivo conditions. Metastases are the primary cause of morbidity and mortality in cancer pati...
Despite recent advances in research, there are still critical lacunae in our basic understanding of the cause, pathogenesis, and natural history of many cancers, especially heterogeneity in patient response to...
The Correction to this article has been published in BMC Cancer 2023 23:768
Germ cell tumors are relatively common in young men. They derive from a non-invasive precursor, called germ cell neoplasia in situ, but the exact pathogenesis is still unknown. Thus, further understanding prov...
Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In th...
This Collection welcomes submission of research articles, data notes, study protocols, and database articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Advances in pre-clinical cancer models" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.